Novel glycosylated VIP analogs: Synthesis, biological activity, and metabolic stability

Journal of Peptide Science

Volumn 14, Issue 3, 2008, Pages 321-328

  Dangoor, David ^a,b   Biondi, Barbara ^c   Gobbo, Marina ^c   Vachutinski, Yelena ^b   Fridkin, Mati ^b   Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

cAMP; Enzymatic degradation; Peptide glycosylation; VIP; VPAC1

Indexed keywords

ARGININE; CYCLIC AMP; LEUCINE; MONOSACCHARIDE; THREONINE; TRYPSIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE[11 GLYCINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[17 NORLEUCINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[2 GLYCINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[22 GLYCINE 17 NORLEUCINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[24 GLYCINE 17 NORLEUCINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[25 GLYCINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[28 GLYCINE 17 NORLEUCINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[7 GLYCINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[9 GLYCINE];

AMINO ACID SEQUENCE; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME DEGRADATION; HUMAN; HUMAN CELL; LIGAND BINDING; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN METABOLISM; PROTEIN STRUCTURE; RECEPTOR BINDING; SOLID PHASE SYNTHESIS;

GLYCOSYLATION; PROTEIN BINDING; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; STRUCTURE-ACTIVITY RELATIONSHIP; VASOACTIVE INTESTINAL PEPTIDE;

MAMMALIA;

EID: 40749114326     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.932     Document Type: Article

References (37)

1. Gozes I, Brenneman DE. VIP: molecular biology and neurobiological function. Mol. Neurobiol. 1989; 3(4): 201-236.
2. Said SI. Vasoactive intestinal polypeptide biologic role in health and disease. Trends Endocrinol. Metab. 1991; 2(3): 107-112.
3. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. International union of pharmacology. XVIII. nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 1998; 50(2): 265-270.
4. Pisegna JR, Wank SA. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc. Natl. Acad. Sci. USA. 1993; 90(13): 6345-6349.
5. Ashur-Fabian O, Giladi E, Brenneman DE, Gozes I. Identification of VIP/ PACAP receptors on rat astrocytes using antisense digodeoxynucleotides. J. Mol. Neurosci. 1997; 9: 211-222.
6. Pilzer I, Gozes I. VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides 2006; 27(11): 2867-2876.
7. Fry DC, Madison VS, Bolin DR, Greeley DN, Toome V, Wegrzynski BB. Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics. Biochemistry 1989; 28(6): 2399-2409.
8. Theriault Y, Boulanger Y, St-Pierre S. Structural determination of the vasoactive intestinal peptide by two-dimensional H-NMR spectroscopy. Biopolymers 1991; 31(4): 459-464.
9. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R, Laburthe M. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J. Biol. Chem. 2000; 275(31): 24003-24012.
10. Onoue S, Matsumoto A, Nagano Y, Ohshima K, Ohmori Y, Yamada S, Kimura R, Yajima T, Kashimoto K. α-Helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences. Eur. J. Pharmacol. 2004; 485: 307-316.
11. Igarashi H, Ito T, Hou W, Mantey SA, Pradhan TK, Ulrich CD II, Hocart SJ, Coy DH, Jensen RT. Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig. J. Pharmacol. Exp. Ther. 2002: 301(1): 37-50.
12. Tan YV, Couvineau A, Murail S, Ceraudo E, Neumann JM, Lacapere JJ, Laburthe M. Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. J. Biol. Chem. 2006; 281(18): 12792-12798.
13. Gozes I, Fridkin M, Hill JM, Brenneman DE. Pharmaceutical VIP. Prospects and problems. Curr. Med. Chem. 1999; 6(11): 1019-1034.
14. Gozes I, Furman S. VIP and drug design [Review]. Curr. Pharm. Des. 2003; 9(6): 483-494.
15. Domschke S, Domschke W, Bloom SR, Mitznegg P, Mitchell J, Lux G, Strunz U. Vasoactive intestinal peptide in man: Pharmacokinetics, metabolic and circulatory effects. Gut 1978; 19: 1049-1053.
16. Negri L, Lattanzi R, Tabacco F, Scolaro B, Rocchi R. Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood-brain barrier penetration. Br. J. Pharmacol. 1998; 124(7): 1516-1522.
17. Negri L, Lattanzi R, Tabacco F, Orru L, Severini C, Scolaro B, Rocchi R. Dermorphin and deltorphin glycosylated analogues: synthesis and antinociceptive activity after systemic administration. J. Med. Chem. 1999; 42(3): 400-404.
18. Gobbo M, Biondi L, Filira F, Gennaro R, Benincasa M, Scolaro B, Rocchi R. Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. J. Med. Chem. 2002; 45(20): 4494-4504.
19. Vandermeers-Piret MC, Vandermeers A, Gourlet P, Ali MH, Waelbroeck M, Robberecht P. Evidence that the lizard helospectin peptides are O-glycosylated. Eur. J. Biochem. 2000; 267(14): 4556-4560.
20. Couvineau A, Fabre C, Gaudin P, Maoret JJ, Laburthe M. Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. Biochemistry 1996; 35(6): 1745-1752.
21. Lins L, Couvineau A, Rouyer-Fessard C, Nicole P, Maoret JJ, Benhamed M, Brasseur R, Thomas A, Laburthe M. The human VPAC1 receptor: three-dimensional model and mutagenesis of the N-terminal domain. J. Biol. Chem. 2001; 276(13): 10153-10160.
22. Filira F, Biondi L, Scolaro, B, Foffani MT, Mammi S, Peggion E, Rocchi R. Solid phase synthesis and conformation of sequential glycosylated polytripeptide sequences related to antifreeze glycoproteins. Int. J. Biol. Macromol. 1990; 12: 41-50.
23. Biondi L, Filira F, Gobbo M, Scolaro B, Rocchi R. Synthesis of glycosylated tuftsins and tultsin-containing IgG fragment undecapeptide. Int. J. Pept. Protein Res. 1991; 37: 112-121.
24. 4I/TFA; compatibility with peptides containing cysteine and aromatic residues. Tetrahedron 1988; 54: 15273-15268.
25. Lelievre V, Meunier AC, Caigneaux E, Falcon J, Muller JM. Differential expression and function of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines. Cell. Signal. 1998; 10(1): 13-26.
26. Dangoor D, Rubinraut S, Fridkin M, Gozes I. Novel extended and branched N-terminal analogs of VIP. Regul. Pept. 2006; 137(1-2): 42-49.
27. Dangoor D, Rubinraut S, Fridkin M, Gozes I. Novel Analogs of VIP with multiple C-terminal domains. Peptides 2007; 28(9): 1622-1630.
28. Summers MA, O'Dorisio MS, Cox MO, Lara-Marquez M, Goetzl EJ. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects. J. Pharmacol. Exp. Ther. 2003; 306(2): 638-645.
29. Gourlet P, Rathe J, De Neef P, Cnudde J, Vandermeers-Piret MC, Waelbroeck M, Robberecht P. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors. Eur. J. Pharmacol. 1998; 354(1): 105-111.
30. Fournier A, Saunders JK, Boulanger Y, St-Pierre SA. Conformational analysis of vasoactive intestinal peptide and related fragments. Ann. N.Y. Acad. Sci. 1988: 527: 51-67.
31. Tams JW, Jorgensen RM, Holm A, Fahrenkrug J. Creation of a selective antagonist and agonist of the rat VPAC1 receptor using a combinatorial approach with VIP 6-23 as a template. Mol. Pharmacol. 2000; 58(5): 1035-1041.
32. Bolin DR, Cottrell J, Garippa R, O'Neill N, Simko B, O'Donnell M. Structure-activity studies of vasoactive intestinal peptide (VIP): cyclic disulfide analogs. Int. J. Pept. Protein Res. 1993; 41(2): 124-132.
33. Gozes I, Fridkin M. A fatty neuropeptide. J. Clin. Invest. 1992; 90: 810-814.
34. Gozes I, Reshef A, Salah D, Rubinraut S, Fridkin M. Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment. Endocrinology 1994; 134(5): 2121-2125.
35. Gololobov G, Noda Y, Sherman S, Rubinstein I, Baranowska-Kortylewicz J, Paul S. Stabilization of vasoactive intestinal peptide by lipids. J. Pharmacol. Exp. Ther. 1998: 285(2): 753-758.
36. Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, Brenneman DE. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 1991; 257(3): 959-966.
37. Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, Davidson A, Rubinraut S, Fridkin M, Brenneman DE. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 1995; 273(1): 161.